New High Blood Pressure Guidelines

The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions.

 

nuevas-guias-de-hipertension

As expected, after the findings of the SPRINT trial and other recently published studies, the treatment goal was lowered and is now below 130/80 mm Hg.


Read also: FOURIER: Evolocumab Found Beneficial for Patients with Peripheral Vascular Disease of Prior MI”.


Blood pressure (BP) levels considered “prehypertension,” according to the Seventh Joint National Committee (JNC 7), are now an “elevated BP” category for patients with systolic 120 to 129 mm Hg and diastolic less than 80 mm Hg, and stage 1 hypertension for patients with systolic 130 to 139 mm Hg and diastolic 80 to 89 mm Hg. Patients with a systolic BP above 140 mm Hg and a diastolic BP above 90 mm Hg are now encompassed in stage 2 hypertension.

 

The consequence of this reclassification is that almost half of the population (45.6%) is now deemed to have hypertension vs. 31.9% according to JNC 7 criteria.


Read also: PRESERVE: IV Bicarbonate and Oral N-Acetylcysteine Do Not Prevent Contrast-Associated Acute Kidney Injury”.


This guideline has been published online before print in Hypertension and the Journal of the American College of Cardiology, and it is the culmination of a process that started in 2013 and comprised the review of over 1000 studies. The resulting document covers the prevention, detection, evaluation, and management of high blood pressure in adults.

 

There is an emphasis on the importance of lifestyle modification, beyond the levels of blood pressure and cardiovascular risk of patients.

 

Original title: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Reference: Whelton PK et al. Hypertension. 2017; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Shortened DAPT Regimens According to the PRECISE-HBR Score

The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Shortened DAPT Regimens According to the PRECISE-HBR Score

The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...